Figure 2.

Rationale for choosing an immunotherapy or a targeted therapy in first line: (a) immunotherapy; (b) targeted therapy.

Oncologists reported their reasons for prescribing an immunotherapy (a) or a targeted therapy (b) to their advanced BRAF-mutant melanoma patients in first line. Results are shown as the percentage of oncologists reporting a given reason for prescribing an immunotherapy or a targeted therapy. The percentages of oncologists are shown within the bars. Totals can sum to over 100% as specialists were allowed to report more than one reason to prescribe an immunotherapy or a targeted therapy. (a) Based on a total of 79 oncologists, of which 29 from academic centers, 17 community-based centers, and 33 private clinics. (b) Based on a total of 84 oncologists, of which 30 from academic centers, 21 community-based centers, and 47 private clinics.